open access

Ahead of Print
ORIGINAL ARTICLES
Published online: 2018-10-09
Submitted: 2018-07-27
Accepted: 2018-09-11
Get Citation

The effects of leptin on F-actin remodelling in type-I diabetes

Celal Guven, Eylem Taskin, Handan Akcakaya, Rustem Nurten
DOI: 10.5603/FM.a2018.0093
·
Pubmed: 30311938

open access

Ahead of Print
ORIGINAL ARTICLES
Published online: 2018-10-09
Submitted: 2018-07-27
Accepted: 2018-09-11

Abstract

Background: The aim of the current study is to investigate the effect of leptin on cytoskeleton structures in both in vivo and in vitro model of diabetes. Materials and methods: For in vivo studies, leptin in different doses (240, and 480 mg/kg) was injected to the diabetic rats after one-week of Streptozotocin (STZ, 55 mg/kg) treatment. Leptin levels were analyzed in serum, liver, and pancreas samples. Hepatic and pancreatic F-and G- actin expressions were determined by Western blotting. For in vitro studies, hepatic and pancreatic primary cell lines were obtained from the control rats. To these cultures, STZ (15 and 30 mM), leptin (50, 60 and 100 ng/ml), and their combinations were applied for one, three, and four weeks. After the treatment period, F-actin was visualized by the Alexa-fluor fluorescent dye. Results: STZ decreased the G-actin in both tissues in vivo. However, leptin caused a dose-dependent increase in G-actin levels while F-actin decreased in both tissues. Moreover, leptin caused the perimembranous condensation of actin filaments and amelioration of F-actin structures in vivo. A dose-dependent corruption of F-actin filament structures was observed in leptin-treated primary cells in vitro, while STZ also caused corruption of these filaments. Co-exposure of STZ and leptin caused the amelioration of F-actin filaments, while the perimembranous condensation was also observed as was in vivo study. Conclusions: Leptin therapy could be a candidate for diabetes, but it should not be ruled out as being important the severity of diabetes and leptin doses.

Abstract

Background: The aim of the current study is to investigate the effect of leptin on cytoskeleton structures in both in vivo and in vitro model of diabetes. Materials and methods: For in vivo studies, leptin in different doses (240, and 480 mg/kg) was injected to the diabetic rats after one-week of Streptozotocin (STZ, 55 mg/kg) treatment. Leptin levels were analyzed in serum, liver, and pancreas samples. Hepatic and pancreatic F-and G- actin expressions were determined by Western blotting. For in vitro studies, hepatic and pancreatic primary cell lines were obtained from the control rats. To these cultures, STZ (15 and 30 mM), leptin (50, 60 and 100 ng/ml), and their combinations were applied for one, three, and four weeks. After the treatment period, F-actin was visualized by the Alexa-fluor fluorescent dye. Results: STZ decreased the G-actin in both tissues in vivo. However, leptin caused a dose-dependent increase in G-actin levels while F-actin decreased in both tissues. Moreover, leptin caused the perimembranous condensation of actin filaments and amelioration of F-actin structures in vivo. A dose-dependent corruption of F-actin filament structures was observed in leptin-treated primary cells in vitro, while STZ also caused corruption of these filaments. Co-exposure of STZ and leptin caused the amelioration of F-actin filaments, while the perimembranous condensation was also observed as was in vivo study. Conclusions: Leptin therapy could be a candidate for diabetes, but it should not be ruled out as being important the severity of diabetes and leptin doses.

Get Citation

Keywords

cytoskeleton, diabetes, F-actin, G-actin, hepatic cells, pancreatic β-cells, leptin therapy

About this article
Title

The effects of leptin on F-actin remodelling in type-I diabetes

Journal

Folia Morphologica

Issue

Ahead of Print

Published online

2018-10-09

DOI

10.5603/FM.a2018.0093

Pubmed

30311938

Keywords

cytoskeleton
diabetes
F-actin
G-actin
hepatic cells
pancreatic β-cells
leptin therapy

Authors

Celal Guven
Eylem Taskin
Handan Akcakaya
Rustem Nurten

References (51)
  1. Arous C, Halban P. The skeleton in the closet: actin cytoskeletal remodeling in β-cell function. Am J Physiol Endocrinol Metab. 2015; 309(7): E611–E620.
  2. Beale EG. Insulin signaling and insulin resistance. J Investig Med. 2013; 61(1): 11–14.
  3. Ceddia RB, Koistinen HA, Zierath JR. Analysis of paradoxical observations on the association between leptin and insulin resistance. Faseb J. 2002; 16: 1163–1176.
  4. Chen PC, Kryukova YN, Shyng SL. Leptin regulates KATP channel trafficking in pancreatic β-cells by a signaling mechanism involving AMP-activated protein kinase (AMPK) and cAMP-dependent protein kinase (PKA). J Biol Chem. 2013; 288(47): 34098–34109.
  5. Considine R, Sinha M, Heiman M, et al. Serum immunoreactive-leptin concentrations in normal-weight and obese humans. N Engl J Med. 1996; 334(5): 292–295.
  6. Cortés VA, Cautivo KM, Rong S. Leptin ameliorates insulin resistance and hepatic steatosis in Agpat2(−/−) lipodystrophic mice independent of hepatocyte leptin receptors. J Lipid Res. 2014; 55: 276–288.
  7. Coupe B, Grit I, Hulin P. Postnatal growth after intrauterine growth restriction alters central leptin signal and energy homeostasis. PLoS One. 2012; 7: e30616.
  8. Dehghany J, Hoboth P, Ivanova A, et al. A Spatial Model of Insulin-Granule Dynamics in Pancreatic β-Cells. Traffic. 2015; 16(8): 797–813.
  9. Denroche H, Quong W, Bruin J, et al. Leptin administration enhances islet transplant performance in diabetic mice. Diabetes. 2013; 62(8): 2738–2746.
  10. Dominguez R, Holmes KC. Actin structure and function. Annu Rev Biophys. 2011; 40: 169–186.
  11. Emekli-Alturfan E, Kasikci E, Yarat A. Tissue factor activities of streptozotocin induced diabetic rat tissues and the effect of peanut consumption. Diabetes Metab Res Rev. 2007; 23(8): 653–658.
  12. Fan F, Ji C, Wu Y, et al. Dynamin 2 regulates biphasic insulin secretion and plasma glucose homeostasis. J Clin Invest. 2015; 125(11): 4026–4041.
  13. Fan H, Patel VA, Longacre A. J.S. Levine, Abnormal regulation of the cytoskeletal regulator Rho typifies macrophages of the major murine models of spontaneous autoimmunity, J Leukoc Biol. 2006; 79: 155–165.
  14. Fofana B, Yao XH, Rampitsch C, et al. Prenatal alcohol exposure alters phosphorylation and glycosylation of proteins in rat offspring liver. Proteomics. 2010; 10(3): 417–434.
  15. Fujikawa T, Chuang JC, Sakata I, et al. Leptin therapy improves insulin-deficient type 1 diabetes by CNS-dependent mechanisms in mice. Proc National Academy Scien. 2010; 107(40): 17391–17396.
  16. Ghantous CM, Azrak Z, Hanache S. Differential Role of Leptin and Adiponectin in Cardiovascular System. Int J endocrinol. 2015; 2015: 534320.
  17. Guven C. The effect of Diazoxide on norepinephrine-induced cardiac hypertrophy, in vitro. Cell Mol Biol (Noisy-le-grand). 2018; 64(10): 50–54.
  18. Harvey J, Ashford MLJ. Leptin in the CNS: much more than a satiety signal. Neuropharmacology. 2003; 44(7): 845–854.
  19. Hien TT, Turczyńska KM, Dahan D, et al. Elevated glucose levels promote contractile and cytoskeletal gene expression in vascular smooth muscle via rho/protein kinase c and actin polymerization. J Biol Chem. 2016; 291(7): 3552–3568.
  20. Ishii S, Kamegai J, Tamura H, et al. Role of ghrelin in streptozotocin-induced diabetic hyperphagia. Endocrinology. 2002; 143(12): 4934–4937.
  21. Justice JD, Brannon PM. Synthesis of amylase by cultured rat pancreatic acinar cells: effects of antecedent diet. J Nutr. 1989; 119(5): 805–812.
  22. Kalwat MA, Thurmond DC. Signaling mechanisms of glucose-induced F-actin remodeling in pancreatic islet β cells. Exp Mol Med. 2013; 45: e37.
  23. Kaya ST, Bozdogan O, Ozarslan TO, et al. The protection of resveratrol and its combination with glibenclamide, but not berberine on the diabetic hearts against reperfusion-induced arrhythmias: the role of myocardial K channel. Arch Physiol Biochem. 2019; 125(2): 114–121.
  24. Kelesidis T, Kelesidis I, Chou S. Narrative review: the role of leptin in human physiology: emerging clinical applications. Ann Internal Med. 2010; 152: 93–100.
  25. Khatri N, Sagar A, Peddada N, et al. Plasma gelsolin levels decrease in diabetic state and increase upon treatment with F-actin depolymerizing versions of gelsolin. J Diabetes Res. 2014; 2014: 152075.
  26. Kim HR, Gallant C, Leavis PC. Cytoskeletal remodeling in differentiated vascular smooth muscle is actin isoform dependent and stimulus dependent. Am J Physiol Cell Physiol. 2008; 295: C768–C778.
  27. King A. The use of animal models in diabetes research. Br J Pharmacol. 2012; 166(3): 877–894.
  28. Klaunig J, Goldblatt P, Hinton D, et al. Mouse liver cell culture. In Vitro. 1981; 17(10): 926–934.
  29. Kohler M, Aufderheide M, Ramm D. Method for the description of differences in the filamentous structure of the cytoskeleton in cultured cells. Toxicol Lett. 1994; 72(1-3): 33–42.
  30. Le Drean G, Segain JP. Connecting metabolism to intestinal barrier function: The role of leptin. Tissue Barriers. 2014; 2: e970940.
  31. Londoño M, Tellez L, Gutierrez R. Physiological low doses of leptin and cholecystokinin induces body weight-loss in juvenile and lean, but not in adult-obese rats. Int J Peptide Res Therap. 2011; 18(1): 77–88.
  32. Lu QY, Jin YS, Zhang Q, et al. Ganoderma lucidum extracts inhibit growth and induce actin polymerization in bladder cancer cells in vitro. Cancer Lett. 2004; 216(1): 9–20.
  33. Maria Z, Yin W, Rubenstein DA. Combined effects of physiologically relevant disturbed wall shear stress and glycated albumin on endothelial cell functions associated with inflammation, thrombosis and cytoskeletal dynamics. J Diabetes Investig. 2014; 5(4): 372–381.
  34. Marroqui L, Gonzalez A, Neco P. Role of leptin in the pancreatic beta-cell: effects and signaling pathways. J Molec Endocrinol. 2012; 49: R9–17.
  35. Millioni R, Iori E, Puricelli L, et al. Abnormal cytoskeletal protein expression in cultured skin fibroblasts from type 1 diabetes mellitus patients with nephropathy: A proteomic approach. Proteomics Clin Appl. 2008; 2(4): 492–503.
  36. Moon HS, Dalamaga M, Kim SY, et al. Leptin's role in lipodystrophic and nonlipodystrophic insulin-resistant and diabetic individuals. Endocrine Rev. 2013; 34(3): 377–412.
  37. Naito M, Fujikura J, Ebihara K, et al. Therapeutic impact of leptin on diabetes, diabetic complications, and longevity in insulin-deficient diabetic mice. Diabetes. 2011; 60(9): 2265–2273.
  38. Paz-Filho G, Mastronardi C, Wong ML, et al. Leptin therapy, insulin sensitivity, and glucose homeostasis. Indian J Endocrinol Metab. 2012; 16(9): 549–555.
  39. Rubenstein JH, Morgenstern H, McConell D, et al. Associations of diabetes mellitus, insulin, leptin, and ghrelin with gastroesophageal reflux and Barrett's esophagus. Gastroenterology. 2013; 145(6): 1237–12344.e1.
  40. Sah S, Singh B, Choudhary S, et al. Animal models of insulin resistance: A review. Pharmacological Reports. 2016; 68(6): 1165–1177.
  41. Shoji T, Nishizawa Y, Emoto M, et al. Renal function and insulin resistance as determinants of plasma leptin levels in patients with NIDDM. Diabetologia. 1997; 40(6): 676–679.
  42. Soetikno V, Sari FR, Veeraveedu PT, et al. Curcumin ameliorates macrophage infiltration by inhibiting NF-κB activation and proinflammatory cytokines in streptozotocin induced-diabetic nephropathy. Nutr Metab (Lond). 2011; 8(1): 35.
  43. Trevelin SC, Carlos D, Beretta M, et al. Diabetes mellitus and sepsis: A Challenging Association. Shock. 2017; 47(3): 276–287.
  44. Tucholski K, Otto-Buczkowska E. The role of leptin in the regulation of carbohydrate metabolism. Endokrynol Pol. 2011; 62: 258–262.
  45. Uzdensky A, Kolpakova E, Juzeniene A, et al. The effect of sub-lethal ALA-PDT on the cytoskeleton and adhesion of cultured human cancer cells. Biochim Biophys Acta. 2005; 1722(1): 43–50.
  46. Visa N, Percipalle P. Nuclear functions of actin. Cold Spring Harb Perspect Biol. 2010; 2(4): a000620.
  47. Wagoner B, Hausman DB, Harris RBS. Direct and indirect effects of leptin on preadipocyte proliferation and differentiation. Am J Physiol Regul Integr Comp Physiol. 2006; 290(6): R1557–R1564.
  48. Wang X, Tang P, Guo F, et al. RhoA regulates Activin B-induced stress fiber formation and migration of bone marrow-derived mesenchymal stromal cell through distinct signaling. Biochim Biophys Acta Gen Subj. 2017; 1861(1 Pt A): 3011–3018.
  49. Widjaja A, Stratton IM, Horn R, et al. UKPDS 20: plasma leptin, obesity, and plasma insulin in type 2 diabetic subjects. J Clin Endocrinol Metab. 1997; 82(2): 654–657.
  50. Yu M, Yuan X, Lu C, et al. mDia1 senses both force and torque during F-actin filament polymerization. Nature Communications. 2017; 8: 1650.
  51. Zhu X, Hu R, Brissova M, et al. Microtubules negatively regulate insulin secretion in pancreatic β cells. Developmental Cell. 2015; 34(6): 656–668.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By  "Via Medica sp. z o.o." sp.k., Świętokrzyska 73, 80–180 Gdańsk, Poland

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl